Michael Wang, MD
Advertisement
Articles by Michael Wang, MD
Advertisement
Latest Updated Articles
Dr. Wang on the FDA Approval of Brexucabtagene Autoleucel in MCLPublished: July 24th 2020 | Updated:
Dr. Wang on Future Research With CAR T-Cell Therapy in MCLPublished: August 5th 2020 | Updated:
Dr. Wang on the Safety and Efficacy of KTE-X19 in R/R MCLPublished: June 20th 2020 | Updated:
Dr. Wang on the Evolution of Treatment in MCLPublished: May 13th 2020 | Updated:
Optimizing MCL Management: Sequencing and Combination StrategiesPublished: January 28th 2022 | Updated:
Dr. Wang on the Safety Profile of Brexucabtagene Autoleucel in Relapsed/Refractory MCLPublished: August 3rd 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5